Xue R. Hou

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Journal: JAMA

Published: June 17, 2026

De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study.

De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study.

Journal: Annals of surgical oncology

Published: May 04, 2026

Dietary inflammatory index and lung cancer risk: multi-cohort evidence and plasma proteomic profiles.

Dietary inflammatory index and lung cancer risk: multi-cohort evidence and plasma proteomic profiles.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 18, 2026

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Recycling plastic wastes to fabricate CNTs decoration on Fe-ZrO2 for the efficient electrocatalytic performance.

Recycling plastic wastes to fabricate CNTs decoration on Fe-ZrO2 for the efficient electrocatalytic performance.

Journal: Environmental research

Published: December 14, 2025

Real-world insights into multidisciplinary management and outcomes of stage III (N2-3) non-small cell lung cancer.

Real-world insights into multidisciplinary management and outcomes of stage III (N2-3) non-small cell lung cancer.

Journal: Translational lung cancer research

Published: October 29, 2025

Insights into the reaction process and mechanism of CNT growth from n-hexane on Fe-based catalysts.

Insights into the reaction process and mechanism of CNT growth from n-hexane on Fe-based catalysts.

Journal: Nanoscale

Published: August 26, 2025

Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.

Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.

Journal: ESMO open

Published: August 18, 2025

Furfural Hydroconversion over Defective Pd/CeO2 Catalysts: More Oxygen Vacancies, Better Catalysis?

Furfural Hydroconversion over Defective Pd/CeO2 Catalysts: More Oxygen Vacancies, Better Catalysis?

Journal: Inorganic chemistry

Published: August 11, 2025

Furmonertinib rechallenge for first-line third-generation EGFR TKI-resistant EGFR-mutant NSCLC: A retrospective propensity score-matched cohort study.

Furmonertinib rechallenge for first-line third-generation EGFR TKI-resistant EGFR-mutant NSCLC: A retrospective propensity score-matched cohort study.

Journal: Cancer treatment and research communications

Published: July 22, 2025

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China.

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China.

Journal: EClinicalMedicine

Published: July 21, 2025

Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases.

Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases.

Journal: NPJ precision oncology

Published: July 21, 2025

Showing 1-12 of 108

Last Updated: 09/26/2026